148 related articles for article (PubMed ID: 18069215)
1. [Changes of plasminogen activator inhibitor (PAI-1) during estrogen replacement therapy].
Zizka Z; Fait T; Vrablík M
Cas Lek Cesk; 2007; 146(11):874-7. PubMed ID: 18069215
[TBL] [Abstract][Full Text] [Related]
2. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
Fait T; Vrablik M; Zizka Z; Kostirova M
Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
[TBL] [Abstract][Full Text] [Related]
3. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
Fait T; Vrablik M; Cibula D; Masata J; Hill M; Trnkova B
Neuro Endocrinol Lett; 2006 Oct; 27(5):665-8. PubMed ID: 17159824
[TBL] [Abstract][Full Text] [Related]
4. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
[TBL] [Abstract][Full Text] [Related]
5. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
6. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
[TBL] [Abstract][Full Text] [Related]
7. Effect of early estrogen replacement therapy on microvascular reactivity in patients after bilateral ovarectomy.
Prázný M; Fait T; Vrablik M
Neuro Endocrinol Lett; 2007 Aug; 28(4):496-501. PubMed ID: 17693976
[TBL] [Abstract][Full Text] [Related]
8. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].
Ciepłuch R; Czestochowska E
Pol Tyg Lek; 1995 Sep; 50(36-39):13-5. PubMed ID: 8650021
[TBL] [Abstract][Full Text] [Related]
9. [Changes in C-reactive protein levels induced by different application forms of estrogen replacement therapy].
Fait T; Vrablík M; Kostírová M; Trnková B
Cas Lek Cesk; 2006; 145(7):571-4; discussion 574. PubMed ID: 16921788
[TBL] [Abstract][Full Text] [Related]
10. [Determination concentrations of tissue factor pathway inhibitor and their changes during estrogen replacement therapy].
Fait T; Trnková B; Kostírova M; Vrablík M
Ceska Gynekol; 2007 Oct; 72(5):343-7. PubMed ID: 18175518
[TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women.
Saucedo R; Basurto L; Zarate A; Martínez C; Hernandez M; Galván R
Gynecol Obstet Invest; 2007; 64(2):61-4. PubMed ID: 17264514
[TBL] [Abstract][Full Text] [Related]
12. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
Sonnet E; Lacut K; Roudaut N; Mottier D; Kerlan V; Oger E
Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
[TBL] [Abstract][Full Text] [Related]
13. Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen.
Kalela A; Jokela H; Lehtimäki T; Uppa H; Kunnas T; Teisala K; Punnonen R; Nikkari ST
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):217-20. PubMed ID: 16337074
[TBL] [Abstract][Full Text] [Related]
14. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers.
Chu MC; Cushman M; Solomon R; Lobo RA
Am J Obstet Gynecol; 2008 Nov; 199(5):526.e1-7. PubMed ID: 18511016
[TBL] [Abstract][Full Text] [Related]
16. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
[TBL] [Abstract][Full Text] [Related]
17. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women.
Maffei S; Mercuri A; Zucchelli GC; Vassalle C
Int J Cardiol; 2006 Feb; 107(2):194-9. PubMed ID: 16412796
[TBL] [Abstract][Full Text] [Related]
18. Effects of early initiated oestrogen replacement therapy on plasma homocysteine levels in women in surgically induced menopause.
Yüksel H; Cobanoğlu M; Odabaşi AR; Sezer SD; Küçük M; Serter M
Gynecol Endocrinol; 2011 Feb; 27(2):101-6. PubMed ID: 20504097
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
[TBL] [Abstract][Full Text] [Related]
20. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey.
Lowe GD; Upton MN; Rumley A; McConnachie A; O'Reilly DS; Watt GC
Thromb Haemost; 2001 Aug; 86(2):550-6. PubMed ID: 11522002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
